Neuroendocrine Tumors of Old Patients in the West of France

Study Overview
=================
Brief Summary
-----------------
Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the management of sporadic and hereditary malignant neuro-ENdocrine Tumor (RENATEN) is in charged of coordinating this specific care. This is part of the French National Cancer INstitute (INCa) Rare Cancer Plan. The project is in the form of an analysis of elderly population (75 years or over) with a diagnosis of neuroendocrine cancer in the western part of the France (Brittany, Pays de Loire, Normandy, Center and a part of New Aquitaine areas) representing a population of more than 12 millions of inhabitants. Oncogeriatric evaluations, specialized meetings, ...would be analysed in order to improve the care of rare cancer patients.

Official Title
-----------------
Neuroendocrine Tumors of Patients Aged of 75 y or Over in the West of France

Conditions
-----------------
Neuroendocrine Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 75 years old or over at the time of diagnosis Patient with G1/G2/G3 neuroendocrine tumor diagnosed by pathological analysis Patient whose medical file was examined by RENATEN (National Network for the treatment of neuro-ENdocrine sporadic and hereditary disease Tumor) meetings or other multidisciplinary consultation meeting between 01/01/2014 and 31/12/2017 Patient with care in private and public centers in the West of France Exclusion Criteria: Patient with cancer other than a neuroendocrine tumor Patient with a G4 neuroendocrine tumor Patient who has objected to the study and collection of his medical data Refusal of participation

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor description : localization of the tumor (digestive or others) provided by scan or anatomopathologic report | statistical analysis (%) | 03/31/2020 | 
| All anticancer treatment description in neuroendocrine tumors of 3 specific histological grade (G1, 2 or 3) | statistical analysis (%) | 03/31/2020 | 
| Histology, differentiation status | qualitative description (text) | 03/31/2020 | 
| mitotic index and proliferation idex of the tumor | statistical analysis (%) | 03/31/2020 | 
| Response rate | statistical analysis (%) | 03/31/2020 | 
| progression free survival | statistical analysis (months) with Kaplan meier analysis; data provided by the medical file | 03/31/2020 | 
| overall survival | statistical analysis (months) with Kaplan meier analysis; data provided by the medical file | 03/31/2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuroendocrine Tumors, 75 y and over patients, Oncogeriatric follow-up, Oncologic care